Table 1 Characteristics critically ill HIV patients coinfected with TB (laboratory-confirmed) diagnosis, including the characteristics of Tuberculosis (TB) presentation and treatment and the prevalence of organ dysfunctions at ICU admission (N = 44)
|  | HIV/AIDS and Tuberculosis (N = 44) | Survivors (N = 21) | Non-survivors (N = 23) | p value |
|---|---|---|---|---|
Age (years) | 34 (19.25–44.5) | 32 (27–42.5) | 36 (30–46) | 0.15 |
Gender (male) | 31 (70Â %) | 14 (67Â %) | 17 (74Â %) | 0.74 |
Nadir CD4a | 54 (17–96) | 73 (30–177) | 23 (14–84) | 0.04 |
Viral load (×103 copies/mm3)b | 113,637 (2,995–365,663) | 35,149 (212.3–300,184) | 169,133 (35,405–419,382) | 0.13 |
Length of time since HIV diagnosis (months) | 5 (1–60) | 1 (1–16) | 28 (1–72) | 0.03 |
cART use while in the ICU | 17 (38.6Â %) | 10 (48Â %) | 7 (30Â %) | 0.35 |
Mechanical ventilation use on ICU day 1 | 21 (48Â %) | 8 (42Â %) | 13 (52Â %) | 0.56 |
Vasoactive drug use on ICU day 1 | 12 (26Â %) | 5 (24Â %) | 7 (27Â %) | 0.99 |
SAPS II score (points) | 47 (37–55) | 48 (37–57) | 46 (38–54) | 0.27 |
SOFA score on day 1 (points) | 4 (1–8) | 1 (0–7) | 5 (2–8) | 0.08 |
Isolated TB pulmonary presentation | 22 (50Â %) | 10 (48Â %) | 12 (52Â %) | 1.00 |
Disseminated TB presentation | 22 (50Â %) | 11 (52Â %) | 11 (48Â %) | 1.00 |
TB treatment before ICU admission | 25 (57Â %) | 11 (52Â %) | 14 (61Â %) | 0.76 |
TB treatment | Â | Â | Â | Â |
 - only by enteral drugs | 16 (36 %) | 10 (48 %) | 6 (26 %) | 0.21 |
 - adding intravenous drugs | 28 (64 %) | 11 (52 %) | 17 (74 %) |  |
TB treatment: Δ ICU admission | 0 (-5–+21) | -5 (-23–+2) | -5 (-21–0) | 0.09 |
TB treatment before ICU | 25 (57Â %) | 11 (52.4Â %) | 14 (61Â %) | 0.76 |
Organ Dysfunctions | Â | Â | Â | Â |
 Cardiovascular | 18 (41 %) | 7 (33.3 %) | 11 (48 %) | 0.37 |
 Respiratory | 15 (34 %) | 5 (24 %) | 10 (43 %) | 0.21 |
 Renal | 14 (32 %) | 5 (24 %) | 9 (39 %) | 0.34 |
 Neurological | 13 (29 %) | 3 (14 %) | 10 (43 %) | 0.04 |
 Hepatic | 9 (20 %) | 5 (24 %) | 4 (17 %) | 0.71 |
 Hematological | 9 (20 %) | 3 (14 %) | 6 (26 %) | 0.46 |